Should I buy or sell scPharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCPH shares. View SCPH analyst ratings or view top-rated stocks .

What is scPharmaceuticals' stock price target for 2024?

2 Wall Street analysts have issued twelve-month price objectives for scPharmaceuticals' shares. Their SCPH share price targets range from $18.00 to $20.00. On average, they expect the company's stock price to reach $19.33 in the next year. This suggests a possible upside of 328.7% from the stock's current price. View analysts price targets for SCPH or view top-rated stocks among Wall Street analysts .

How have SCPH shares performed in 2024?

scPharmaceuticals' stock was trading at $6.27 at the beginning of 2024. Since then, SCPH stock has decreased by 28.1% and is now trading at $4.51. View the best growth stocks for 2024 here .

When is scPharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SCPH earnings forecast .

How were scPharmaceuticals' earnings last quarter?

scPharmaceuticals Inc. (NASDAQ:SCPH) issued its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.07. The business earned $6.10 million during the quarter, compared to analysts' expectations of $6.10 million. scPharmaceuticals had a negative net margin of 403.22% and a negative trailing twelve-month return on equity of 97.18%.

What other stocks do shareholders of scPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS) , Dynavax Technologies (DVAX) , Fulcrum Therapeutics (FULC) , ImmunoGen (IMGN) , VBI Vaccines (VBIV) , Selecta Biosciences (SELB) , SCYNEXIS (SCYX) , Syndax Pharmaceuticals (SNDX) , Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX) .

When did scPharmaceuticals IPO?

scPharmaceuticals (SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Who are scPharmaceuticals' major shareholders?

scPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Thomasville National Bank (0.10%). Insiders that own company stock include 5Am Partners Iv, Llc, Jack A Khattar , John H Tucker and Orbimed Advisors Llc. View institutional ownership trends .

How do I buy shares of scPharmaceuticals?

Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SCPH

scPharmaceuticals (SCPH) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free SCPH Stock Alerts

$4.51

+0.09 (+2.04%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.25
▼
$4.52
50-Day Range: $4.42
▼
$6.22
52-Week Range: $4.25
▼
$12.75

Volume: 223,805 shs
Average Volume: 229,347 shs
Market Capitalization: $162.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.33

Get scPharmaceuticals alerts:

scPharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 328.7% Upside
$19.33 Price Target
Short Interest: Bearish
19.70% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.82
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.47) to ($0.66) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.16 out of 5 stars

Medical Sector

314th out of 918 stocks

Pharmaceutical Preparations Industry

130th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
scPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
scPharmaceuticals has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
19.70% of the float of scPharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
scPharmaceuticals has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.
Change versus previous month
Short interest in scPharmaceuticals has recently decreased by 0.65%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
scPharmaceuticals does not currently pay a dividend.
Dividend Growth
scPharmaceuticals does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
scPharmaceuticals has received a 70.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.
Environmental Sustainability
The Environmental Impact score for scPharmaceuticals is -0.82.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for scPharmaceuticals this week, compared to 1 article on an average week.
MarketBeat Follows
Only 2 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, scPharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.68% of the stock of scPharmaceuticals is held by insiders.
Percentage Held by Institutions
89.52% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for scPharmaceuticals are expected to grow in the coming year, from ($1.47) to ($0.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of scPharmaceuticals is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of scPharmaceuticals is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
scPharmaceuticals has a P/B Ratio of 4.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

Click here to see Louis' new video for yourself.

About scPharmaceuticals Stock (NASDAQ:SCPH)

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

SCPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SCPH Stock News Headlines

April 10, 2024 | msn.com

Novel Biannual Antihypertensive Shows Potential for Combination Therapy

March 27, 2024 | finance.yahoo.com

Those who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 62%

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

March 20, 2024 | finanznachrichten.de

scPharmaceuticals, Inc.: scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

March 16, 2024 | insidermonkey.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript

March 16, 2024 | finance.yahoo.com

SCPH Apr 2024 5.000 put

March 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for scPharmaceuticals Amidst Revenue Surge and Solid Financial Footing

March 14, 2024 | finance.yahoo.com

Q4 2023 scPharmaceuticals Inc Earnings Call

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 14, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)

March 14, 2024 | markets.businessinsider.com

Strong Buy Recommendation for scPharmaceuticals on Furoscix’s Successful Launch and Growth Prospects

March 13, 2024 | finance.yahoo.com

scPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX Growth

March 13, 2024 | globenewswire.com

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

March 12, 2024 | msn.com

scPharmaceuticals Q4 2023 Earnings Preview

March 11, 2024 | markets.businessinsider.com

Craig-Hallum Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)

March 9, 2024 | markets.businessinsider.com

scPharmaceuticals Inc Registered Shs hosts conference call for investors

March 6, 2024 | globenewswire.com

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

February 28, 2024 | globenewswire.com

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

February 21, 2024 | benzinga.com

scPharmaceuticals Stock (NASDAQ:SCPH), Short Interest Report

January 15, 2024 | finanznachrichten.de

DelveInsight Business Research, LLP: Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight

January 8, 2024 | msn.com

Top 10 stocks with the highest short interest on Wall Street

January 7, 2024 | markets.businessinsider.com

Strong Buy: scPharmaceuticals’ Furoscix Shows Robust Sales Growth and Solid Financial Health

January 5, 2024 | markets.businessinsider.com

Buy Rating for scPharmaceuticals: Furoscix’s Market Traction and Growth Potential Drive Positive Valuation

January 5, 2024 | finanznachrichten.de

scPharmaceuticals, Inc.: scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX Revenue

January 4, 2024 | finance.yahoo.com

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

January 3, 2024 | markets.businessinsider.com

Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

December 23, 2023 | msn.com

VYGR, VSAT and SNBR are among after hour movers

See More Headlines

Receive SCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SCPH
CUSIP: N/A
CIK: 1604950
Web: www.scpharma.com
Phone: (617) 517-0730
Fax: N/A
Employees: 135
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $19.33
High Stock Price Target: $20.00
Low Stock Price Target: $18.00
Potential Upside/Downside: +328.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.42)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-54,810,000.00
Net Margins: -403.22%
Pretax Margin: -403.22%
Return on Equity: -97.18%
Return on Assets: -49.59%

Debt

Debt-to-Equity Ratio: 1.04
Current Ratio: 7.08
Quick Ratio: 6.40

Sales & Book Value

Annual Sales: $13.59 million
Price / Sales: 11.96
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.04 per share
Price / Book: 4.34

Miscellaneous

Outstanding Shares: 36,050,000
Free Float: 34,367,000
Market Cap: $162.59 million
Optionable: Optionable
Beta: 0.06

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. John H. Tucker (Age 61)
President, CEO, Principal Executive Officer & Director
Comp: $981.56k
Ms. Rachael Nokes (Age 48)
CFO & Principal Accounting Officer
Comp: $573.8k
Mr. Michael D. Hassman
Senior Vice President of Technical Operations
Katherine Taudvin
Vice President of Corporate Affairs & Human Resources
Dr. John Mohr Pharm.D.
Senior Vice President of Clinical Development & Medical Affairs
Steve Parsons
Senior Vice President of Commercial

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SCPH Stock Analysis - Frequently Asked Questions

Should I buy or sell scPharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCPH shares.
View SCPH analyst ratings or view top-rated stocks.
What is scPharmaceuticals' stock price target for 2024?: 2 Wall Street analysts have issued twelve-month price objectives for scPharmaceuticals' shares. Their SCPH share price targets range from $18.00 to $20.00. On average, they expect the company's stock price to reach $19.33 in the next year. This suggests a possible upside of 328.7% from the stock's current price.
View analysts price targets for SCPH or view top-rated stocks among Wall Street analysts.
How have SCPH shares performed in 2024?: scPharmaceuticals' stock was trading at $6.27 at the beginning of 2024. Since then, SCPH stock has decreased by 28.1% and is now trading at $4.51.
View the best growth stocks for 2024 here.
When is scPharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SCPH earnings forecast.
How were scPharmaceuticals' earnings last quarter?: scPharmaceuticals Inc. (NASDAQ:SCPH) issued its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.07. The business earned $6.10 million during the quarter, compared to analysts' expectations of $6.10 million. scPharmaceuticals had a negative net margin of 403.22% and a negative trailing twelve-month return on equity of 97.18%.

What other stocks do shareholders of scPharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).
When did scPharmaceuticals IPO?: scPharmaceuticals (SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.
Who are scPharmaceuticals' major shareholders?: scPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Thomasville National Bank (0.10%). Insiders that own company stock include 5Am Partners Iv, Llc, Jack A Khattar, John H Tucker and Orbimed Advisors Llc.
View institutional ownership trends.
How do I buy shares of scPharmaceuticals?: Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SCPH) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial